Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | ABAT | P80404 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31192807 | 0.87 | ALDH1A1 (0.59) | ALDH1A1MAPTALOX12LMNASMN1; SMN2 | |
| SCHEMBL20109301 | 0.87 | ALDH1A1 (0.59) | ALDH1A1MAPTALOX12LMNASMN1; SMN2 | |
| SCHEMBL18756478 | 0.82 | LMNA (0.71) | ALDH1A1MAPTALOX12LMNASMN1; SMN2 | |
| SCHEMBL11209835 | 0.79 | ALDH1A1 (0.65) | ALDH1A1MAPTALOX12LMNASMN1; SMN2 | |
| SCHEMBL1275764 | 0.79 | KMT2A (0.72) | ALDH1A1MAPTALOX12LMNASMN1; SMN2 | |
| SCHEMBL2459615 | 0.78 | SMN1; SMN2 (0.67) | ALDH1A1MAPTALOX12LMNASMN1; SMN2 | |
| SCHEMBL8956279 | 0.78 | KMT2A (0.78) | ALDH1A1MAPTALOX12LMNASMN1; SMN2 | |
| SCHEMBL10596294 | 0.78 | LMNA (0.61) | ALDH1A1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL21327696 | 0.76 | MAOA (0.51) | ALDH1A1MAPTALOX12LMNAKMT2A | |
| SCHEMBL5458013 | 0.76 | KMT2A (1.00) | ALDH1A1MAPTALOX12LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249701-A1 | Cyclic amine CCR5 receptor antagonists | TEIJIN LIMITED | 2007-10-25 | — | — | US | disclosed |
| US-20070040151-A1 | Two-component initiator system (amine-free) with very good storage stability and particular suitability for acid systems | HERAEUS KULZER GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
| US-20070010509-A1 | Cycloamine ccr5 receptor antagonists | TEIJIN PHARMA LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-4713382-A | N-phenyl-4-phenyl-1-piperazinecarboxamidines and related compounds as antiarrhythmic agents | SYNTEX (U.S.A.) INC. (US) | 1987-12-15 | — | — | US | disclosed |
| EP-0204265-A1 | N-Phenyl-4-phenyl-1-piperazine carboxamidines and related compounds as antiarrhythmic agents | LABORATOIRES SYNTEX S.A. (FR) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010509-A1 | Cycloamine ccr5 receptor antagonists | CCR5, CCR2, CCR1 | ALDH1A1 1322/4885MAPT 3786/4885ALOX12 642/4885 |
| US-20070249701-A1 | Cyclic amine CCR5 receptor antagonists | CCR5, CCR7, CCR2 | ALDH1A1 966/4885MAPT 3908/4885ALOX12 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.